• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Login
  • Contact

Don’t invest unless you’re prepared to lose all your money invested. This is a high risk investment. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Take 2 mins to learn more

The o2h human health knowledge intensive KI EIS fund

First HMRC approved KI fund in the UK that will invest in knowledge-intensive EIS qualifying companies focused on novel drug discovery and AI technologies
Request Prospectus
Invest
as seen on
o2h-ventures
o2h-ventures
o2h-ventures
o2h-ventures
o2h-ventures
fund highlights

Therapeutics, or coming up with the next life-saving drug requires going through vast quantities of data and making various calculated guesses on how the human body will behave, this costs millions and often billions. AI has the potential to help make sense of this data in that it helps to see patterns and the AI will help make smarter predictions on how to deploy resources on research and experiments.

  • Access to the most exciting scientific ideas through its live grassroots working relationships in the biotech community for over 20 years.
  • Operating from their proprietary 2.7 acre Mill SciTech Park the fund can incubate life science companies leading to more effective decision making.
  • The fund is structured to be EIS compliant providing income, inheritance and capital gains tax breaks for UK taxpayers.
About o2h ventures
fund overview
Minimum Investment
£25k
Target Return
IRR 20%
Fund SizeTarget £ 10m
Tax AdvantagesUnder new "Approved EIS funds" investor are eligible for added tax advantages. A carry-back rule enable investors to set their relief against income tax liabilities in the year before the fund closes.
DiversificationAim to build investors an initial Portfolio of 5-10 unquoted and/or AIM-listed companies.
Tax Relief30% income tax relief *
DifferentiationTwo part investment focus of Access & Incubation, providing unique opportunities and reducing investment risk by being deeply involved.

For more details on the fund, please download fund documents

Request Prospectus

For more details on the fund, please download fund documents

Request Prospectus

EIS tax relief is very attractive for UK tax payers

You invest £50k

EIS gives you £15k tax relief from HMRC

EIS gives you £25k tax relief from HMRC

COMPANY VALUE DOUBLES

Investment now worth £100k

£50k profit

+ £15k income tax relief

- £10k performance incentive

= £55k net profit

VALUE STAYS THE SAME

Investment still worth £50k

£0 profit

+ £15k income tax relief

- £0 performance incentive

= £15k net profit

COMPANY FAILS

Investment now worth £0

£50k loss

+ £15k income tax relief

+ £15,750 loss relief *

- £0 performance incentive

= £19,250 capital loss

* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees

Need help in understanding how investing in EIS works?

Contact Support Team

Need help in understanding how investing in EIS works?

Contact Support Team
our team
o2h-ventures

Sunil Shah

Chief Executive Officer

Sunil's Biography

o2h-ventures
close

Sunil Shah

Chief Executive Officer

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University

o2h-ventures

Prashant Shah

Director

Prashant's Biography

o2h-ventures
close

Prashant Shah

Director

A serial entrepreneur having begun a career with the Strategy group of at Accenture followed by co-founding two companies in the technology and life sciences sector. The second of these companies focused on drug discovery was acquired by a public company. Prashant co-founded o2h Ventures which is involved in seeding, incubating and investing in early stage life science and technology companies. Prashant has a BEng, MSc and an MPhil in Management.

o2h-ventures

Andy Morley

Chief Scientific Officer

Andy's Biography

o2h-ventures
close

Andy Morley

Chief Scientific Officer

Creative and innovative medicinal chemist with extensive knowledge and expertise. Twenty five years experience working in the pharmaceutical industry.

o2h-ventures

Catherine Beech

Independent Representative to the Investment Advisory Panel

Catherine Beech Biography

o2h-ventures
close

Catherine Beech

Independent Representative to the Investment Advisory Panel

Catherine has over 25 years of experience in biotech, pharmaceutical and as a venture investor. She is currently the CEO of Exonate for which she was one of the founders leading the spin-out from Nottingham University. Catherine has a degree in medicine from Birmingham University and in 2008 was awarded the OBE for services to technology and innovation.

See All
portfolio
o2h-ventures

Applying artificial intelligence on large-scale multiomic data to develop the next generation of cardiovascular disease drug targets

Read more
o2h-ventures

Developing a platform of novel small molecule RGD integrin inhibitors with superior drug-like qualities

Read more
o2h-ventures

Developing medicines to treat patients with neurological conditions.

Read more
o2h-ventures

Using artificial intelligence, augmented reality and games to reduce stress and anxiety and improve patient outcomes

Using artificial intelligence, augmented reality and games to reduce stress and anxiety and improve patient outcomes
Read more
o2h-ventures

Intelligent lead generation for clinical trial recruitment

Intelligent lead generation for clinical trial recruitment
Read more
See All Portfolio

Subscribe to Get Latest Updates on Our Portfolio Companies

    news
    • o2h Ventures - Best EIS investment manager o2h Ventures qualified as a finalist as Best EIS Manager – Specialist at Growth Investor Awards 2023 14 August, 2023
    • o2h Ventures shortlisted in UKBAA 23 o2h Ventures selected as finalist for best seed VC in UKBAA awards 2023 14 June, 2023
    • o2h Ventures - Finalist in EISA Awards 2023 o2h Ventures recognized as a finalist for the EISA Impact Award for 2023 8 June, 2023
    See All News
    funds registered on
    o2h-ventures
    o2h-ventures
    o2h-ventures
    o2h-ventures

    Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.

    Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.

    o2h-ventures
    The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
    Useful Links
    • About Us
    • Blog
    • Documents Centre
    • Contact Us
    • Team
    News
    • o2h Ventures qualified as a finalist as Best EIS Manager – Specialist at Growth Investor Awards 2023
    • o2h Ventures selected as finalist for best seed VC in UKBAA awards 2023
    • o2h Ventures recognized as a finalist for the EISA Impact Award for 2023
    Connect with us
    • linkedin
    • twitter
    • instagram
    • facebook
    © 2023 o2h ventures
    • Privacy Policy
    • Blog
    • Contact us
    This website is a financial promotion approved by o2h Ventures Ltd for the purposes of section 21 Financial Services and Markets Act 2000 relating to the communication of invitations or inducements to engage in investment activity. o2h ventures Limited is regulated and authorised by the Financial Conduct Authority. The FCA firm reference number is 812245 and further information can be found on the Financial Services Register.

    Risk Information

    Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

    What are the key risks?

    1 – You could lose all the money you invest

    • If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

    2 – You are unlikely to be protected if something goes wrong

    • Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

    • Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

    3 – You won’t get your money back quickly

    • Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

    • The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

    • If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

    4 – Don’t put all your eggs in one basket

    • Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

    • A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

    5 – The value of your investment can be reduced

    • The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

    • These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

    If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)